-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Reiterates Outperform on Ligand Pharmaceuticals, Raises Price Target to $326

Benzinga·08/03/2026 14:23:53
Listen to the news
Oppenheimer analyst Leland Gershell reiterates Ligand Pharmaceuticals (NASDAQ:LGND) with a Outperform and raises the price target from $285 to $326.